124 related articles for article (PubMed ID: 37805854)
1. [Construction and functional analysis of EGFRvIII CAR-T cells co-expressing IL-15 and CCL19].
Chen W; Xian N; Lin S; Liao W; Chen M
Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3787-3799. PubMed ID: 37805854
[TBL] [Abstract][Full Text] [Related]
2. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
Huang W; Liu Y; Hu Y; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
[TBL] [Abstract][Full Text] [Related]
3. [Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma].
Feng DD; Chen XH; Guo JJ; Wang KK; Zhang XM; Gao JM
Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):657-665. PubMed ID: 34289557
[No Abstract] [Full Text] [Related]
4. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
Goto S; Sakoda Y; Adachi K; Sekido Y; Yano S; Eto M; Tamada K
Cancer Immunol Immunother; 2021 Sep; 70(9):2503-2515. PubMed ID: 33559069
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
6. Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability.
Hu JF; Wang ZW; Liao CY; Chen ZW; Kang FP; Lin CF; Lin TS; Huang L; Tian YF; Chen S
Front Immunol; 2022; 13():958960. PubMed ID: 35990619
[TBL] [Abstract][Full Text] [Related]
7. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
[TBL] [Abstract][Full Text] [Related]
8. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
10. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model.
Sasaki T; Sakoda Y; Adachi K; Tokunaga Y; Tamada K
Cancer Med; 2023 Jun; 12(11):12569-12580. PubMed ID: 37031457
[TBL] [Abstract][Full Text] [Related]
12. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
14. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer.
Zhou Z; Li J; Hong J; Chen S; Chen M; Wang L; Lin W; Ye Y
Front Immunol; 2022; 13():1002361. PubMed ID: 36618357
[TBL] [Abstract][Full Text] [Related]
16. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.
Murakami T; Nakazawa T; Natsume A; Nishimura F; Nakamura M; Matsuda R; Omoto K; Tanaka Y; Shida Y; Park YS; Motoyama Y; Nakagawa I; Yamada S; Tamura K; Takeshima Y; Takamura Y; Wakabayashi T; Nakase H
Anticancer Res; 2018 Sep; 38(9):5049-5056. PubMed ID: 30194149
[TBL] [Abstract][Full Text] [Related]
17. Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma.
Meng M; Wu YC
J Immunol Res; 2021; 2021():1782728. PubMed ID: 34527749
[TBL] [Abstract][Full Text] [Related]
18. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
[TBL] [Abstract][Full Text] [Related]
19. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
[TBL] [Abstract][Full Text] [Related]
20. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
Zhu H; You Y; Shen Z; Shi L
Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]